Diagnostic accuracy of Siemens SARS-CoV-2 Antigen (CoV2Ag) chemiluminescent immunoassay for diagnosing acute SARS-CoV-2 infection: a pooled analysis.

Abstract

This article provides a critical literature review and pooled analysis of diagnostic accuracy of the fully-automated Siemens SARS-CoV-2 Antigen (CoV2Ag) chemiluminescent immunoassay for diagnosis of acute SARS-CoV-2 infections. An electronic search was conducted in Scopus, PubMed and medRxiv using the keywords ["Siemens AND CoV2Ag"] OR ["Siemens AND SARS-CoV-2 AND antigen"] for capturing studies that investigated the accuracy of Siemens CoV2Ag for diagnosing acute SARS-CoV-2 infection against a reference SARS-CoV-2 molecular test. The retrieved information was used for constructing a 2×2 table and for calculating pooled diagnostic sensitivity, specificity, Summary Receiver Operating Characteristic Curve (SROC) and Agreement. This study followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) reporting checklist. Four studies totalling 1,310 respiratory samples (612 with high viral load) were finally included in our analysis. The cumulative area under the curve, accuracy, sensitivity, specificity, were 0.964 (95% CI, 0.957-0.971), 86.9% (95% CI, 84.9-88.7%), 0.79 (95% CI, 0.76-0.82) and 0.98 (95% CI, 0.96-0.99), respectively. The negative (NPV) and positive (PPV) predictive values were 0.77 (0.74-0.79) and 0.98 (95% CI, 0.96-99), respectively. The diagnostic sensitivity in samples with high viral load (i.e.,Ct<29-30) was 0.95 (95% CI, 0.93-0.97). The Siemens CoV2Ag fully-automated and high-throughput immunoassay approximates the minimum performance criteria for general SARS-CoV-2 antigen testing and displays excellent performance in samples with high viral load, thus representing a valuable screening solution for risk assessment in COVID-19 and for limiting viral spread.